Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 8.54 USD -0.12%
Market Cap: 801.1m USD

Operating Margin
Chimerix Inc

-45 550.5%
Current
-35 343%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-45 550.5%
=
Operating Profit
-96.6m
/
Revenue
212k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Chimerix Inc
NASDAQ:CMRX
787.5m USD
-45 550%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.2B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
145B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
130.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.1B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Chimerix Inc
Glance View

Market Cap
787.5m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
4.99 USD
Overvaluation 42%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-45 550.5%
=
Operating Profit
-96.6m
/
Revenue
212k
What is the Operating Margin of Chimerix Inc?

Based on Chimerix Inc's most recent financial statements, the company has Operating Margin of -45 550.5%.

Back to Top